Quick answer: A patent portfolio can support an investment thesis, but a grant does not automatically increase company valuation or remove challenge risk. Investors should connect the issued and pending claims to the product, company ownership, remaining term and commercial alternatives.
Start with what the company actually owns
List the issued patents and applications, relevant jurisdictions, named inventors, assignments, co-owners and material licenses. Confirm that the company has the rights it expects to use or transfer. Employment alone should not be treated as a substitute for reviewing the assignment chain and applicable agreements.
Map claims to commercial advantage
Identify which limitations cover the product’s important technical features, what a competitor could change, and what evidence would be available to assess use. A portfolio count does not answer those questions. For applications, distinguish the claims sought from the narrower or different claims that may eventually issue.
Assess risk without assuming a guaranteed outcome
Review prior art, prosecution history, eligibility, disclosure support, disputes, remaining term and maintenance. A patent gives a right to exclude within its enforceable scope, not a general right to sell the product or an immunity from other patents. The USPTO patent essentials explain that basic distinction.
PTAB institution decisions and changing procedures may affect particular disputes, but discretionary denial is not a validity judgment or a guarantee that a portfolio will face only one forum. For a dated example, see the March 2025 Motorola v. Stellar decision. It should not be extrapolated into an automatic company-valuation claim.
Turn diligence findings into a decision
Prioritize the gaps that matter to the financing or acquisition: an unresolved assignment, a claim-to-product mismatch, a key deadline, an expensive prosecution stage or an existing license restriction. State assumptions and unresolved questions clearly. Value may also depend on know-how, regulatory position, customer evidence, execution and the company’s resources.
Coordinate legal and product work
For biotechnology and pharmaceutical development companies, compare the claimed subject matter and remaining term with the actual development plan. Mergers and acquisitions IP diligence connects those assets to the transaction. Outside general counsel can coordinate ownership, commercial agreements and company obligations.
Jeff Schell helps innovators connect patent portfolios with product and business priorities. Book a Free Consultation to discuss the portfolio and the decision you need to make.
